Loading
Liver Disease Diagnosis and Treatment · Journal article
The Egyptian Journal of Internal Medicine · August 18, 2026
Early or partial results. Treat as a signal, not a conclusion.
This small case-control study found significant reductions in serum SIRT1 levels and gene expression in patients with metabolic syndrome and MASLD compared to healthy controls, with correlations to metabolic and inflammatory markers and high discriminative accuracy (91.2%) on ROC analysis. The findings are suggestive of SIRT1's potential as a non-invasive diagnostic marker but require external validation in larger prospective cohorts and evaluation of clinical utility before adoption in clinical practice.
Case-control study. Group 1: 17 patients with metabolic syndrome and metabolic dysfunction-associated steatotic liver disease (MASLD). Group 2: 17 healthy individuals.. Intervention: Measurement of serum SIRT1 levels and SIRT1 gene expression. Compared with: Healthy controls without metabolic syndrome or MASLD. n = 34.
Serum SIRT1 levels and gene expression declined significantly with increasing steatosis grade in metabolic syndrome with MASLD patients Positive correlation between SIRT1 gene expression and HDL-C (r = 0.60, P < 0.001) and serum SIRT1 and HDL-C (r = 0.33, P = 0.04) Negative correlations: SIRT1 serum levels with triglycerides (r = -0.30, P = 0.04) and CRP (r = -0.35, P = 0.01); gene expression with waist circumference (r = -0.50, P = 0.004), total cholesterol (r = -0.34, P = 0.04), and LDL-C (r = -0.49, P = 0.004)
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Although the reported diagnostic accuracy of serum SIRT1 is high, the small sample size and lack of prospective validation or external cohort testing limit confidence in clinical applicability. Further validation in independent populations and evaluation against existing diagnostic modalities (imaging, biopsy) is necessary before consideration for clinical use.
Small uncontrolled case-control study (n=17 per group) examining biomarker associations and diagnostic accuracy in a cross-sectional design; suggestive of SIRT1's potential as a marker but lacks prospective validation, treatment outcome data, and external replication.
As stated by the source record.
Quoted from the source exactly as published.
Although the reported diagnostic accuracy of serum SIRT1 is high, the small sample size and lack of prospective validation or external cohort testing limit confidence in clinical applicability. Further validation in independent populations and evaluation against existing diagnostic modalities (imaging, biopsy) is necessary before consideration for clinical use.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Background Metabolic syndrome is a cluster of conditions, including abdominal obesity, dyslipidemia, hypertension, and impaired glucose metabolism, that significantly increase the risk of cardiovascular disease and type 2 diabetes mellitus (T2DM). Metabolic dysfunction-associated steatotic liver disease (MASLD) was recently introduced to describe fatty liver disease linked to metabolic dysfunction. MASLD is the global primary cause of chronic liver disease nowadays. Additionally, it is a main driver of hepatic-related complications and deaths. This study was performed to evaluate serum sirtuin 1 (SIRT1) levels and gene expression in metabolic syndrome with MASLD patients and their associations with steatosis grade. Materials and methods The study participants were divided into 2 groups. Group 1 included 17 patients with metabolic syndrome with MASLD. Group 2 included 17 healthy individuals. Blood samples were collected after an overnight fast to measure fasting plasma glucose (FPG), lipid profile, and liver enzymes. Inflammatory markers (ESR and CRP) were also measured. SIRT1 serum levels were measured by enzyme-linked immunosorbent assay (ELISA). Total RNA was extracted from whole blood, and the relative SIRT1 gene expression was calculated. Results There was a significant decline in serum SIRT1 levels and gene expression with increasing grades of steatosis among metabolic syndrome with MASLD patients. Additionally, there were statistically significant positive correlations between SIRT1 gene and protein expression and HDL-C among metabolic syndrome with MASLD patients ( r = 0.60, P < 0.001 and r = 0.33, P = 0.04, respectively). Moreover, SIRT1 serum levels exhibited significant negative correlations with TG ( r =-0.30, P = 0.04) and CRP ( r =-0.35, P = 0.01). SIRT1 gene expression showed significant negative correlations with waist circumference ( r =-0.50, P = 0.004), total cholesterol ( r = -0.34, P = 0.04), and LDL-C ( r =-0.49, P = 0.004). Furthermore, receiver operating characteristic (ROC) curve analysis revealed that serum SIRT1 exhibited an accuracy of 91.2% in discriminating metabolic syndrome with MASLD with significant validity ( P < 0.001). Sensitivity was 88.2%, and specificity was 94.1%. Conclusions SIRT1 reduction at gene and protein levels is associated with the metabolic and inflammatory burden of metabolic syndrome with MASLD. The strong ROC performance of serum SIRT1 suggests its potential role as a non-invasive marker for identifying metabolic syndrome with MASLD.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.